Postdoctoral Scientist, Structural Biology - United States
Want to know company name or location? Company managed [?]
|External Posting Title||Postdoctoral Scientist, Structural Biology|
|Job Description||We have a postdoctoral position open to study Wnt signaling and its role in neurodegeneration. A number of studies have shown the importance of the Wnt signaling pathway in the survival and maintenance of dopaminergic neurons. The candidate will conduct original and significant basic investigations in elucidating the mechanisms through which this pathway regulates these processes. The laboratory explores these pathways using a structural (x-ray crystallography), biophysical and biochemical approaches.|
The successful candidate will have opportunities to collaborate internally and externally to succeed in contributing towards research that will result in novel and important discoveries leading to understanding the pathway biology and also publications in top tier scientific journals.
|Location||Cambridge, MA, US|
|Job Category||Postdoctoral Fellow|
|Qualifications||Candidates should have a doctoral degree and at least one first-author paper published or accepted in a peer-reviewed journal, with technical expertise in techniques like x-ray crystallography, SPR, ITC, DSF, cloning, expression, purification and characterization of proteins. Candidates with cell biology/ developmental signaling pathway experience would be a plus. Exceptionally qualified candidates with limited x-ray crystallography experience may also be considered. Excellent oral and written communication skills are required.|
|Education||Ph. D in a life science or related field|
|About Biogen||Corporate Overview|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.
One of the pioneers in biotechnology, Biogen was founded in 1978 and today serves patients in nearly 90 countries. Our global headquarters and R&D operations are located in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland, world-class manufacturing facilities in Research Triangle Park, North Carolina, USA and Hillerod, Denmark, and affiliate locations around the world.
We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.
For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer’s disease, Parkinson’s disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.
Biogen is revolutionizing biologics manufacturing, developing the industry’s most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.
Our Corporate Citizenship
The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek’s 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science’s list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.
Nearest Major Market: Cambridge
Nearest Secondary Market: Boston
Job Segment: Scientist, Scientific, Biochemistry, Biotech, Science, Engineering, Research